Why Females Are So Much Serious About Their Face Skin?

Researchers from USP , Ribeirão Preto discovered a treatment to destroy cancer cells in a few weeks . This new technique uses medicine as a protein that already exists in our body .

In May , researchers believed that a mouse convicted of a skin cancer he would have two months to live at most. In June , he began a new treatment , developed in molecular and cellular cancer biology laboratory. Twenty days later , the tumor disappeared .

According to the research coordinator , Enilza Espreáfico , the discovery is important. " We unraveled step by step in the pathway that induces cell death ."

The treatment is the result of a survey from the observation of protein called myosin 5A .

Scientists have discovered that it moves into the cell like a freight train , taking a different substance in each car . One molecule carries an extremely dangerous , BMF , which is capable of killing a cell.

The novelty is that the researchers managed to open the door of the wagon and use BMF to destroy cancer cells .

Images taken through a microscope shows cells of malignant tumor fading until it disappeared three weeks after the first application of an aqueous solution that acts on the DNA of the mouse. " We managed to kill the cell melanoma is a type of highly aggressive and resistant to conventional therapies and chemotherapies tumor," explains Antonio Carlos Borges , a researcher at USP .

In addition to treating skin cancer therapy may also be used to combat carcinomas , such as the uterus.

For Brazilian scientists , the reduction of tumors achieved in the laboratory is an important advance in the fight against resistance that tumors often have to currently available treatments . The discovery opens up new possibilities for the development of therapies and medications.

" Our ambition now is to use this molecular tool to produce a drug that can be injected ma person who has a tumor and she causes tumor cell death without causing any damage to the body ," explains Enilza .

No comment, be the first to comment.